New York Senate Bill S07839

New York 2025-2026 Regular Session

• Introduced: 5/9/25
• Refer: 5/9/25
• Refer: 1/7/26

Caption

Prohibits the sale of medical adhesives and bandages containing perfluoroalkyl and polyfluoroalkyl substances; provides penalties for violations.

Impact

The enactment of S07839 would lead to significant changes in state law concerning the control and regulation of medical products. By establishing a prohibition on certain harmful substances, the bill intends to enhance public health and environmental safety. As PFAS are linked to various health issues, including cancer and hormonal disruptions, this legislation aligns New York with a growing movement towards regulating and reducing the presence of these chemicals in consumer products. In addition to promoting health, the bill could incentivize manufacturers to develop safer alternatives and innovate within the medical adhesive market.

Summary

Bill S07839, introduced in the New York Senate, aims to prohibit the sale of medical adhesives and bandages that contain perfluoroalkyl and polyfluoroalkyl substances (PFAS). These substances have been increasingly scrutinized for their potential detrimental effects on human health and the environment. The bill specifically targets products intended for medical use, thereby mandating that medical adhesives and bandages must not contain PFAS as intentionally added chemicals or exceed levels established by the Department of Environmental Conservation. The implementation of this legislation would take effect after December 31, 2026.

Contention

However, the bill is likely to face challenges and opposition, particularly from manufacturers and retailers of medical adhesives who may argue about the feasibility of compliance and the potential economic burden it may impose. Some stakeholders may express concerns that the restrictions could lead to shortages of essential medical supplies, potentially impacting patient care. This could lead to debates in legislative discussions on the balance between public health priorities and the interests of manufacturers. Continuous efforts will be needed to educate the public and stakeholders about the significance of this bill in protecting health and the environment.